Researchers studied how alpha-lipoic acid (ALA), a natural substance found in some foods, might help prevent nerve damage in people with diabetes. Using diabetic rats and nerve cells in the lab, they found that ALA appeared to improve nerve function and protect nerve fibers by helping tiny energy-producing structures called mitochondria move properly within nerve cells. The study suggests ALA works by activating specific proteins that control how these energy factories are transported along nerves. While these early results are promising, more research in humans is needed before doctors can recommend ALA as a standard treatment for diabetic nerve damage.
The Quick Take
- What they studied: Whether alpha-lipoic acid (ALA) could prevent or reduce nerve damage caused by diabetes by improving how energy-producing structures move within nerve cells
- Who participated: The study used 40 male rats divided into three groups: healthy rats (control group), diabetic rats without treatment, and diabetic rats given ALA. Researchers also tested ALA on nerve cells grown in the laboratory
- Key finding: Rats treated with ALA showed better nerve function (improved nerve signal speed and pain sensitivity) and had higher levels of protective proteins compared to untreated diabetic rats. The ALA appeared to work by helping mitochondria (the cell’s energy factories) move more efficiently within nerve fibers
- What it means for you: This research suggests ALA might help protect nerves in people with diabetes, but these are early-stage animal studies. More research in humans is needed before ALA can be recommended as a treatment. If you have diabetes and are interested in ALA, talk to your doctor first
The Research Details
This was an animal and laboratory study published in PLOS ONE. Researchers first created diabetes in rats using a special diet and injection, then gave some rats ALA supplements for 12 weeks while others received no treatment. They measured how well the rats’ nerves worked and examined nerve tissue under a microscope. In a separate part of the study, they grew nerve cells in dishes, exposed them to high sugar and fat (to mimic diabetes), and tested whether ALA could protect these cells.
The researchers measured several things to understand how ALA worked: they checked how fast nerve signals traveled, tested how sensitive the rats’ paws were to touch, looked at nerve tissue structure, and measured levels of specific proteins involved in moving energy factories within cells. They used special staining techniques to see these proteins and used Western blotting (a lab method) to measure protein amounts.
Understanding how ALA might protect nerves is important because diabetic nerve damage (called neuropathy) affects millions of people and currently has limited treatment options. By studying the specific mechanisms—how ALA helps energy-producing structures move within nerve cells—researchers can better understand whether this approach might work in humans and how to develop better treatments
This study has both strengths and limitations. Strengths include using both animal models and laboratory cell studies, measuring multiple markers of nerve function, and examining the specific proteins involved in the protective mechanism. Limitations include that it was only done in rats and lab cells (not humans), the sample size was relatively small, and results from animal studies don’t always translate to humans. The study was published in a reputable journal (PLOS ONE), which suggests it passed peer review, but animal studies are considered early-stage evidence
What the Results Show
Rats treated with ALA showed significant improvements in nerve function compared to untreated diabetic rats. Specifically, the speed at which nerve signals traveled increased, and the rats’ sensitivity to touch (measured by how quickly they pulled their paws away from pressure) improved. When researchers examined the nerve tissue under a microscope, they found that ALA-treated rats had better-preserved nerve structure compared to untreated diabetic rats.
At the molecular level, ALA increased levels of two important proteins: p-AMPK and p-CREB. These proteins act like switches that turn on protective processes in cells. ALA also changed how proteins involved in moving mitochondria (energy factories) within nerve cells were expressed. Specifically, it increased KIF5A, a protein that moves mitochondria forward along nerve fibers, and decreased DYNC1I2, a protein that moves them backward. This shift suggests ALA helps position energy factories where they’re needed most in nerve cells.
In the laboratory cell studies, nerve cells treated with ALA showed longer, healthier axons (the long extensions of nerve cells) compared to cells exposed to high sugar and fat without ALA treatment. The protective proteins were also more active in ALA-treated cells
The study found that the protective effects appeared to work through a specific cellular pathway: the AMPK/CREB signaling pathway. This pathway is like a communication system inside cells that controls whether protective genes are turned on or off. ALA appeared to activate this pathway, which then triggered the changes in mitochondrial transport proteins. This suggests the mechanism is fairly specific and could potentially be targeted with other treatments in the future
Alpha-lipoic acid has been studied for diabetes complications before, and some research suggests it may help with nerve pain and function. This study adds to that body of research by identifying a specific mechanism—how ALA helps mitochondria move within nerve cells—that might explain why it could be protective. However, most previous human studies on ALA for diabetic nerve damage have shown modest benefits, so this animal study provides a foundation for understanding why larger human trials might be worthwhile
This study has several important limitations. First, it was conducted in rats, not humans, so results may not apply directly to people. Second, the study only lasted 12 weeks, so we don’t know if benefits continue longer or if there are long-term side effects. Third, the dose of ALA used in rats (60 mg/kg/day) may not translate directly to appropriate human doses. Fourth, the study didn’t compare ALA to other existing treatments for diabetic nerve damage. Finally, the sample size was relatively small (15 rats per group), which means results should be confirmed in larger studies before drawing firm conclusions
The Bottom Line
Based on this animal study alone, ALA cannot be recommended as a standard treatment for diabetic nerve damage. However, the research is interesting enough to warrant further human studies. If you have diabetes and are interested in trying ALA, discuss it with your doctor first. Some people do take ALA supplements, and it appears generally safe at standard doses, but evidence for effectiveness in humans remains limited. (Confidence level: Low—this is early-stage animal research)
This research is most relevant to people with diabetes who are concerned about nerve damage, researchers studying diabetes complications, and pharmaceutical companies developing new treatments. People with type 1 or type 2 diabetes experiencing nerve pain or numbness might be interested in this research, but should not self-treat without medical guidance. Healthcare providers treating diabetic nerve damage should be aware of this research but should recognize it’s preliminary
In the rat study, benefits appeared after 12 weeks of treatment. If ALA were to be tested in humans, it would likely take several months to see effects, and larger clinical trials would need to run for at least 6-12 months to establish safety and effectiveness. Don’t expect immediate results if you try ALA—any benefits would likely develop gradually over weeks to months
Want to Apply This Research?
- If a user has diabetes and wants to track nerve health, they could monitor: (1) any changes in numbness or tingling in feet/hands (rate 1-10 weekly), (2) pain levels during daily activities, and (3) ability to feel temperature or sharp sensations in feet. Track these weekly and share results with their doctor
- Users interested in this research could: (1) discuss ALA supplementation with their doctor and get approval before starting, (2) if approved, take ALA consistently at the recommended dose, (3) maintain good blood sugar control through diet and medication (the most important factor), and (4) monitor nerve symptoms weekly using the app’s tracking feature
- Set up a monthly check-in to review nerve symptom trends. Compare current symptoms to baseline from 3 months prior. If using ALA, track consistency of taking the supplement. Share monthly summaries with healthcare provider. If symptoms worsen or new symptoms develop, notify doctor immediately rather than waiting for the monthly review
This article discusses early-stage animal research on alpha-lipoic acid and diabetic nerve damage. This research has not been tested in humans and should not be used to make treatment decisions. Diabetic nerve damage is a serious condition that requires medical supervision. Do not start, stop, or change any diabetes medications or supplements without consulting your doctor first. If you experience numbness, tingling, or pain in your feet or hands, contact your healthcare provider immediately. This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.